- Report
- October 2024
- 189 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Eprazinone is a respiratory drug used to treat asthma and chronic obstructive pulmonary disease (COPD). It is a long-acting beta-agonist (LABA) that works by relaxing the muscles of the airways, allowing more air to flow in and out of the lungs. It is often used in combination with an inhaled corticosteroid (ICS) to provide better control of symptoms. Eprazinone is available in both brand-name and generic forms.
Eprazinone is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2019. It is currently available in the US, Canada, and Europe. It is also being studied for use in other countries.
Eprazinone is marketed by several pharmaceutical companies, including GlaxoSmithKline, Merck, and Novartis. Other companies involved in the market include Mylan, Teva, and Sun Pharmaceuticals. Show Less Read more